Rare Disease Treatment Market Size (2024 - 2029)

The rare disease treatment market is projected to experience significant growth over the forecast period, driven by an increase in the prevalence of rare diseases and supportive government initiatives. The market's expansion is further supported by rising research and development activities, the introduction of novel therapeutics, and favorable policies. Despite challenges such as high treatment costs and limited awareness, the market is recovering from the impacts of the COVID-19 pandemic and is expected to maintain a stable growth trajectory.

Market Size of Rare Disease Treatment Industry

Rare Disease Treatment Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 216.65 Billion
Market Size (2029) USD 380.62 Billion
CAGR (2024 - 2029) 11.93 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration High

Major Players

Rare Disease Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Rare Disease Treatment Market Analysis

The Rare Disease Treatment Market size is estimated at USD 216.65 billion in 2024, and is expected to reach USD 380.62 billion by 2029, at a CAGR of 11.93% during the forecast period (2024-2029).

Megatrends Shaping the Market: The Rare Disease Treatment Market is experiencing robust growth, driven by two primary megatrends: the rising global prevalence of rare diseases and the intensifying focus on research and development (R&D) for novel therapeutics. These megatrends are supported by increasing awareness, favorable government policies, and a surge in new drug launches. Collectively, these factors are propelling the market forward and shaping the future of the rare disease treatment landscape.

Increase in the Number of Rare Disease Cases: A key driver for market expansion is the growing prevalence of rare diseases worldwide. According to GlobalGenes, more than 400 million people are affected by rare diseases globally, with approximately 7,000 known conditions. This substantial patient population drives demand for specialized treatments, especially since 80% of these diseases have genetic origins. The discovery of 250 to 280 new rare diseases annually further emphasizes the expanding market scope and the need for continuous innovation in treatment approaches.

Rising R&D Activities for Novel Therapeutics and Drugs: R&D is at the heart of growth in the rare disease treatment market. Increased funding and strategic public-private initiatives are catalyzing innovation. For example, the U.S. Food and Drug Administration (FDA) has committed over USD 38 million in funding over four years to support clinical trials and research tools for rare diseases. Such investments are critical in addressing the unmet medical needs of rare disease patients, fostering significant market growth.

Increase in the Number of New Drug Launches: The number of FDA-approved drugs for rare diseases, many of which are classified as orphan drugs, is growing rapidly. Recent approvals like Xenpozyme, designed for treating Acid Sphingomyelinase Deficiency (ASMD), highlight the sector’s focus on rare disease drug development. These new treatments not only offer hope to patients but also contribute to market expansion by providing more options to address the specific needs of those affected by rare diseases.

Favorable Government Policies: Government initiatives play a crucial role in accelerating market growth. Countries like India and the United States are introducing policies that support rare disease research and treatment. For instance, in August 2024, India added 63 rare diseases to its National Policy for Rare Diseases, following recommendations from the Central Technical Committee for Rare Diseases (CTCRD). Similarly, the U.S. FDA's Accelerating Rare Disease Cures (ARC) Program is designed to fast-track the development of treatment options for rare diseases, creating a favorable environment for market players.

Strategic Initiatives by Market Players: Strategic collaborations, mergers, and acquisitions are shaping the competitive landscape. Companies like AstraZeneca and CanSino Biologics Inc. are partnering to enhance rare disease diagnosis and treatment access in China. Such initiatives are expected to drive innovation, expand market reach, and further stimulate market growth in the years ahead.

Rare Disease Treatment Industry Segmentation

As per the scope of this report, rare diseases are diseases that affect only a small population compared to the general population. Rare diseases are region specific in that a rare disease could be rare in one region while it is common in another. Rare diseases may be chronic or incurable, though many short-term medical conditions are also rare diseases.

The rare disease treatment market is segmented by drug type (biologics and non-biologics), therapeutic area (genetic diseases, neurological diseases, oncology, infectious diseases, cardiovascular diseases, and other therapeutic areas), mode of administration (oral, injection, and other modes of administration) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values (in USD million) for the above segments.

By Drug Type
Biologics
Non-biologics
By Therapeutic Area
Genetic Diseases
Neurological Diseases
Oncology
Infectious Diseases
Cardiovascular Diseases
Other Therapeutic Area
By Mode of Administration
Oral
Injection
Other Modes of Administration
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Rare Disease Treatment Market Size Summary

The rare disease treatment market is poised for significant growth, driven by an increasing number of rare disease cases and supportive government policies. The market is recovering from the disruptions caused by the COVID-19 pandemic, which had led to the suspension of clinical trials and elective procedures. The demand for advanced treatment solutions is expected to rise due to the high prevalence of rare diseases globally, with a substantial portion being hereditary and chronic. Initiatives such as the US FDA's Accelerating Rare disease Cures Program and India's National Policy for Rare Diseases are fostering research and development, expediting drug approvals, and enhancing access to treatments. These efforts, coupled with the launch of novel therapeutics and biologics, are anticipated to propel market growth over the forecast period.

North America is expected to hold a significant share of the market, attributed to the high prevalence of rare diseases and a robust healthcare infrastructure. The region's market growth is further supported by strategic collaborations and partnerships among key players, such as CanSino Biologics Inc. and AstraZeneca, aimed at improving diagnosis and treatment access. The competitive landscape is dominated by major companies like Amgen Inc., AstraZeneca, and Biomarin Pharmaceuticals, which are actively engaging in mergers, acquisitions, and product launches to strengthen their market position. Despite challenges such as high treatment costs and limited awareness, the market is set to expand, driven by innovation in treatment and increasing product approvals.

Explore More

Rare Disease Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increase in the Number of Rare Disease Cases

      2. 1.2.2 Rising R&D Activities for Novel Therapeutics and Drugs and Increase in the Number of New Drug Launches and Favorable Government Policies

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Awareness Regarding Rare Disease Treatment

      2. 1.3.2 High Cost of Treatment

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - in USD)

    1. 2.1 By Drug Type

      1. 2.1.1 Biologics

      2. 2.1.2 Non-biologics

    2. 2.2 By Therapeutic Area

      1. 2.2.1 Genetic Diseases

      2. 2.2.2 Neurological Diseases

      3. 2.2.3 Oncology

      4. 2.2.4 Infectious Diseases

      5. 2.2.5 Cardiovascular Diseases

      6. 2.2.6 Other Therapeutic Area

    3. 2.3 By Mode of Administration

      1. 2.3.1 Oral

      2. 2.3.2 Injection

      3. 2.3.3 Other Modes of Administration

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Rare Disease Treatment Market Size FAQs

The Rare Disease Treatment Market size is expected to reach USD 216.65 billion in 2024 and grow at a CAGR of 11.93% to reach USD 380.62 billion by 2029.

In 2024, the Rare Disease Treatment Market size is expected to reach USD 216.65 billion.

Rare Disease Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)